Skip to main content
Screenshot of carvykti.com

Live website intelligence

carvykti.com

Patient Website | CARVYKTI® (ciltacabtagene autoleucel)

Learn about CARVYKTI®, a type of CAR-T cell therapy for adult patients. See Safety & Prescribing information, including Boxed Warning.

Last refresh

Updated 13d ago

Analyst read

Professional

5/100 trustHealth & FitnessStale snapshot

Detected stack

React

Quick read

How to read carvykti.com quickly

carvykti.com looks like health & fitness. Traffic estimates are limited, so use the trust and structure modules first. Current AI trust scoring is 5/100.

What to do next

  • The stack appears to include React.
  • Open the Traffic tab if you need audience scale and geography before outreach.
  • Open the Business tab if trust, monetization, or positioning is your first decision filter.

Provider Completeness

42/56 fields populated (75%)

11 providers

Providers with missing fields

traffic: 0/10radar: 0/4
View field-level status

visual: 4/4

All expected fields present

meta: 3/3

All expected fields present

seo: 5/5

All expected fields present

dns: 4/4

All expected fields present

ads: 5/5

All expected fields present

publisher: 5/5

All expected fields present

files: 3/3

All expected fields present

traffic: 0/10

Missing: monthlyVisits, globalRank, countryRank, bounceRate, avgVisitDuration, pagesPerVisit, topCountry, topRegions, topKeywords, trafficSources

whois: 6/6

All expected fields present

radar: 0/4

Missing: globalRank, rankBucket, categories, sourceTimestamp

ai: 7/7

All expected fields present

Why this module matters

Business signals help answer “is this a real opportunity?”

Use the business tab to understand trust, monetization, audience fit, and brand posture before you spend time on outreach, partnerships, or competitive teardown work.

  • Trust score and sentiment are your first risk screen.
  • Business summary and audience notes speed up qualification.
  • Ads and monetization patterns reveal how the site captures value.

Business Intelligence

Business Profile

CARVYKTI® (ciltacabtagene autoleucel) is a prescription CAR-T cell therapy for adult patients with relapsed or refractory multiple myeloma, developed by Legend Biotech in partnership with Johnson & Johnson. The website serves as a patient education and treatment information portal.

Business ModelPharmaceutical/Biotech - Prescription Drug Marketing
Target AudienceAdult multiple myeloma patients, caregivers, oncologists, and healthcare providers seeking information about CAR-T cell therapy treatment options

Classification

CategoryHealth & Fitness
Sub-CategoryMedicine & Health
pharmaceuticalCAR-T therapymultiple myelomacancer treatmentbiotechpatient educationFDA approved drugJohnson & Johnson

Trust & Risk

Trust Assessment

Trust Score5/100
SentimentProfessional
Spam DetectionClean

Google Ads Transparency

Is AdvertiserActive Advertiser
Advertiser Names
Johnson \u0026 Johnson
Advertiser IDs
AR16205673242948534273
Ad Count1
has_advertiser_idhas_creative_results

Publisher Monetization

ads.txtMissing
Direct Sellers0
Reseller Sellers0

Monetization Signals

missing_ads_txt

AI Visual Analysis

Design StyleCorporate Healthcare
VibeTrustworthy, Professional, Compassionate
UI Score7/100
Detected Logo TextCARVYKTI

IAB Taxonomy

IAB CategoryHealth & Fitness
IAB Sub-CategoryMedicine & Health
Confidence97%
pharmaceuticalCAR-T therapymultiple myelomacancer treatmentbiotechpatient educationFDA approved drugJohnson & Johnson

Business Insights

Business Model

Pharmaceutical/Biotech - Prescription Drug Marketing model detected

Trust Level

Low trust with 5/100 score

Audience

Adult multiple myeloma patients, caregivers, oncologists, and healthcare providers seeking information about CAR-T cell therapy treatment options

Keep exploring

Keep exploring from this report

Good pSEO pages should not strand the visitor. These links keep the journey moving through adjacent directories and comparable live reports.

Need fresh data for another site? Trigger a fresh analysis or open the directory to continue browsing.